期刊文献+
共找到640篇文章
< 1 2 32 >
每页显示 20 50 100
The expression of cyclooxygenase-2 (COX-2) and p16 in non-Hodgkin's lymphomas and its clinical significance 被引量:4
1
作者 Xigui Yang Huazhi Zhang +1 位作者 Ling Wei Liya Jia 《The Chinese-German Journal of Clinical Oncology》 CAS 2009年第2期104-109,共6页
Objective: To investigate the expression of cyclooxygenase-2 (COX-2) and p16 proteins in non-Hodgkin's lymphomas (NHL) and their relationship with the genesis and progress of it. Methods: The expression of COX-... Objective: To investigate the expression of cyclooxygenase-2 (COX-2) and p16 proteins in non-Hodgkin's lymphomas (NHL) and their relationship with the genesis and progress of it. Methods: The expression of COX-2 and p16 protein were studied in the lymph nodes tissue from 60 NHL patients and 10 control patients with non-malignant diseases by flow cytometry. Results: Positive rate of COX-2 protein expression in NHL tissues (63.3%, 38/60) was higher than that in normal lymphaden tissues (0, 0/10). The difference was significant between the two groups (P 〈 0.01). Expression of COX-2 protein was related with the clinical stage of NHL. In stage Ⅰ + Ⅱ patients, it was significantly lower (35.0% ± 54.6%) than that in stage Ⅲ + Ⅳ patients (84.6% ±87.5%) (P 〈 0.01). In different sex, age, tumor malignant degree, IPI grade, extranodal involvement and B symptoms groups, the differences of COX-2 expression were not statistically significant (P 〉 0.05). Positive rate of p16 protein expression (41.7%, 25/60) in NHL' was statistically lower than that in normal lymphomas (100%, 10/10) (P 〈 0.01). Expression of p16 protein was related to malignant degree of NHL. The positive rates of p16 protein in low malignant degree tissues (64.7%, 11/17) was higher than that in high malignant degree tissues (14.3%, 2/14) (P 〈 0.05). Positive rates of p16 protein of NHL tissues in different sex, age, IPI grade, extranodal involvement, clinical stages and B symptoms were not statistically significant (P 〉 0.05). The p16 protein expression in COX-2 positive patients was 47.4% (18/38), and in negative patients it was 31.8% (7/22). There was no statistically difference between them (P 〉 0.05). Correlation analysis revealed there was no correlation between expression of COX-2 and p16 protein. Conclusion: Both COX-2 and p16 protein may all have relationship with the genesis and progress of NHL. The expression of COX-2 protein in NHL may be a poor prognostic indicator. COX-2 and p16 protein probably have different mechanisms in the genesis and progress of NHL. Their relationship is firstly put forward in this article and needed further studying. 展开更多
关键词 non-hodgkin's lymphomas p16 protein CYCLOOXYGENAsE-2 flow cytometry
下载PDF
CHOP-like Regimen in Combination with Rituximab and Peginterferon Alpha-2b in Newly-diagnosed Diffuse Large B-cell Non-Hodgkin's Lymphoma: Experience in a Chinese Center
2
作者 Shu-qing LU Jian-min YANG Xian-min SONG Li CHEN Wei-ping ZHANG Xiao-qian XU Xiong NI Chong-mei HUANG Yi HE Jian-min WANG 《Clinical oncology and cancer researeh》 CAS CSCD 2010年第2期103-109,共7页
OBJECTIVE To evaluate the efficacy of rituximab combined with CHOP-like regimen with or without IFN in patients newly diagnosed diffuse large B-cell Non-Hodgkin's lymphoma (DLBCL).METHODS From January 2003 to July ... OBJECTIVE To evaluate the efficacy of rituximab combined with CHOP-like regimen with or without IFN in patients newly diagnosed diffuse large B-cell Non-Hodgkin's lymphoma (DLBCL).METHODS From January 2003 to July 2008, 51 patients received CHOP-like chemotherapy (cyclophosphamide 750 mg/m2, epirubicin 80 mg/m2, vindesine 2.8 mg/m2 on day 1, and prednisolone 100 mg/day on day 1 to day 5). Thirty-one patients received CHOPR-like treatment (rituximab 375 mg/m2 1 day before CHOP-like chemotherapy). Twenty patients received CHOP-like regimen in combination with peginterferon (pegIFN) (1μg/kg on day 5) and rituximab (on day 6).RESULTS -The CR (complete remission) rate in the CHOPR-like (with or without pegIFN) group and in the CHOP-like group was 78.4% and 45.1% (P = 0.005), respectively. The estimated mean time of overall survival (OS) in the CHOPR-like group and CHOP- like group was 58.7 ± 2.8 and 36.4 ±3.4 months, respectively (P = 0.002). The rates of CR and OR (overall remission) in CHOPR- like with IFN arm were 85.0% and 95.0%, and the rates of those in CHOPR-like without IFN arm were 74.2% and 87.0% (P 〉 0.05). The estimated mean time of 4-year-PFS (progression- free survival) in CHOPR-like with IFN arm and in CHOPR-like without IFN arm was 62.9 ±3.0 months and 51.0 ± 4.6 months (P = 0.092), respectively. In the CHOPR-like with IFN arm, no patient relapsed after achieving CR, while the estimated rate of 4-year- DFS (disease-free survival) in the patients who reached CR in the CHOPR-like without IFN arm was (63.4 ± 19.3)% (P = 0.061). CONCLUSION Rituximab combined with CHOP-like chemotherapy improved the prognosis of DLBCL patients. The IFN may help to improve the quality and duration of response of DLBCL patients treated with rituximab and CHOP-like regimen. 展开更多
关键词 CHOP-like RITUXIMAB peginte feron alpha-2b non-hodgkin's lymphoma diffuse large B-cell.
下载PDF
Primary Pleural Extranodal Non-Hodgkin's Lymphoma Presenting As Pleural Thickening-A Case Report
3
作者 Pradipta Guha Debasis Sarkar +3 位作者 Arindam Ray Indranil Thakur Sekhar Mukherjee Sanjoy Kumar Chatterjee 《Clinical oncology and cancer researeh》 CAS CSCD 2011年第1期47-50,共4页
Primary pleural lymphoma is a rare entity that has been described in association with human immunodeficiency virus (HIV) infection or pyothorax. This paper reports on a 27 year old man with no history of HIV infecti... Primary pleural lymphoma is a rare entity that has been described in association with human immunodeficiency virus (HIV) infection or pyothorax. This paper reports on a 27 year old man with no history of HIV infection or pyothorax who presented with progressive dyspnea and heaviness of chest.Chest radiography revealed complete opacification of the left hemithorax, and contrast enhanced computed tomography showed large left pleural effusion and homogeneous, extensive thickening of the parietal pleura. CT guided biopsy of thickened pleura is suggestive of non-Hodgkin's lymphoma-T cell lymphoblastic variety. Physicians should be aware of this rare location of primary pleural lymphoma manifested by thickening of the pleura. 展开更多
关键词 non-hodgkin's lymphoma T cell lymphoblastic type lymphoma extranodal NK-T-cell
下载PDF
Analysis of Prognostic Factors in 108 Patients with Non-Hodgkin's Lymphoma
4
作者 Jia-ming TANG An-wei CHEN +3 位作者 Wen-ming PENG Zi-ke QIN Guo-hua LIANG Qian QU 《Clinical oncology and cancer researeh》 CAS CSCD 2010年第1期44-47,共4页
OBJECTIVE To analyze the prognostic factors in patients with non-Hodgkin's lymphoma (NHL) and to investigate the prognostic value of the absolute lymphocyte count (ALC) in peripheral blood in NHL patients at admi... OBJECTIVE To analyze the prognostic factors in patients with non-Hodgkin's lymphoma (NHL) and to investigate the prognostic value of the absolute lymphocyte count (ALC) in peripheral blood in NHL patients at admission. METHODS The clinical features and follow-up data from 108 NHL patients whose diagnosis was confirmed through pathologic examination during a period from January 2000 to January 2008 were reviewed. SPSS 14.0 package was used for statistical analysis, and the Kaplan-Meier curve method for assessment of survival probability. Furthermore, the Cox regression model was utilized for multivariate analysis for all parameters which were statistically significant and confirmed by univariate analysis. RESULTS In the 108 NHL patients, the male-female ratio was approximately 1.5 : 1 and the median age was 48 years. Before treatment, 61.1% of the patients had stage I and II disease, based on the Ann Arbor Clinical Classification. The ECOG performance status (PS) score reached a range from 0 to 1 in about 93% of total patients, and an elevated serum lactate dehydrogenase (LDH) was seen in 19.2%. Based on the international prognostic index (IPI) score, 80.6% of patients were in the low risk group. On admission, 35.2% of patients had an ALC 〈 1 × 10^9/L. Anemia, i.e. hemoglobin (Hb) 〈 110 g/L was seen in 29.6% and B-symptoms in 26.9% of patients. The mean value of Hb was 129.2 + 17.5 g/L in patients with ALC 〉 1 x 109/L (n = 70) and 98.1 + 20.6 g/L in those with ALC 〈 1 × 10^9/L (n = 38), and the difference between the 2 groups was statistically significant (P 〈 0.05). With a median follow-up period of 2 years, the median survival time was 2.3 years among all patients. The 2-year and 5-year overall survival (OS) rates were 73.2% and 39.6%, respectively. It was shown by univariate analysis that ALC 〈 1 × 10^9/L, Hb ≤ 110 g/L, B-symptoms, and the IPI 〉 2 were statistically significant unfavorable prognostic factors in NHL patients. Multivariate analysis revealed that ALC 〈 1 × 10^9/L, B-symptoms, and the IPI 〉 2 were independent unfavorable prognostic factors in NHL patients. CONCLUSION The numerical value of ALC and the presence" of B-symptoms are prognostic factors independent of IPI in NHL patients. Clinically, determining prognosis based on the IPI combined with simple clinical parameters, such as the numerical value of ALC and B-symptom status, might be of more practical value in determining individualized treatment regimens for NHL patients. 展开更多
关键词 lymphocyte count non-hodgkin's lymphoma prognosis.
下载PDF
Superior Antitumor Activity of Rituximab-Conjugated and Maytansine-Loaded PLA-TPGS Nanoparticles in Xenograft Models for Non-Hodgkin's Lymphoma
5
作者 Xiaolong Tang Yuan Fang +9 位作者 Yongqiang Zhu Jingjing Dai Ganxun Wang Yajuan Liu Rongbo Zhang Shuyu Cai Jinfeng Zhang Keliang Song Lifa Xu Yong Liang 《Journal of Pharmacy and Pharmacology》 2014年第6期336-348,共13页
The increased incidence ofNHL (non-Hodgkin's lymphoma), along with its high mortality rate and pronounced resistance to therapy pose an enormous challenge. Both traditional therapeutic strategies and recently devel... The increased incidence ofNHL (non-Hodgkin's lymphoma), along with its high mortality rate and pronounced resistance to therapy pose an enormous challenge. Both traditional therapeutic strategies and recently developed therapeutic strategies against NHL such as chemoimmunotherapy and targeted therapy have drawbacks. Therefore, novel therapeutic approaches for NHL are urgently needed. Maytansine-loaded PLA-TPGS (polyethylene glycol 1000 succinate-polylactide) nanoparticles were synthesized. And then, rituximab targeting NHL was conjugated together by using EDC (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide) as a coupling agent. The in vitro/vivo antitumor activity was evaluated by Raji cell proliferation inhibition and nude mice xenograft tumor models for NHL. Both the rituximab-conjugated and maytansine-loaded PLA-TPGS nanoparticles (maytansine-NPs (Nanoparticles)-rituximab) and maytansine-loaded PLA-TPGS nanoparticles (maytansine-NPs) presented significant inhibition effect on Raji cell proliferation in a concentration-dependent manner. Compared with conventional maytansine and maytansine-NPs, maytansine-NPs-rituximab showed significantly enhanced cytotoxicity and increased cell apoptosis in Raji cells. The maytansine-NPs-rituximab described in this paper might be a potential formulation for targeting chemotherapy and immunotherapy to CD20+ B cell malignancies. 展开更多
关键词 non-hodgkin's lymphoma CD20 monoclonal antibodies apoptosis active targeting nanoparticles chemoimmunotherapy.
下载PDF
Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphoma 被引量:6
6
作者 Lin Gui Xiaohong Han +10 位作者 Xiaohui He Yuanyuan Song Jiarui Yao Jianliang Yang Peng Liu Yan Qin Shuxiang Zhang Weijing Zhang Wenlin Gai Liangzhi Xie Yuankai Shi 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2016年第2期197-208,共12页
Objective: This study was designed to determine the safety, pharmacokinetics and biologic effects of a humanmouse chimeric anti-CD20 monoclonal antibody (SCT400) in Chinese padents with CD20-positive B-cell non- Ho... Objective: This study was designed to determine the safety, pharmacokinetics and biologic effects of a humanmouse chimeric anti-CD20 monoclonal antibody (SCT400) in Chinese padents with CD20-positive B-cell non- Hodgkin's lymphoma (CD20 B-cell NHL). SCT400 has an identical amino acid sequence as rituximab, with the exception of one amino acid in the CH1 domain of the heavy chain, which is common in Asians. Methods: Fifteen patients with CD20+ B-cell NHL received dose-escalating SCT400 infusions (250 mg/m2: n=3; 375 mg/m2: n=9; 500 mg/m2: n=3) once weekly for 4 consecutive weeks with a 24-week follow-up period. The data of all patients were collected for pharmacoklnetics and pharmacodynamics analyses. Results: No dose-limiting toxicities were observed. Most drug-related adverse events were grade 1 or 2. Two patients had grade 3 or 4 ncutropenia. Under premedication, the drug-related infusion reaction was mild. A rapid, profound and durable depletion of circulating B cells was observed in all dose groups without significant effects on T cell count, natural killer (NK) cell count or immunoglobulin levels. No patient developed anti- SCT400 antibodies during the course of the study. SCT400 serum half-life (Tin), maximum concentration (Cmax and area under the curve (AUC) generally increased between the first and fourth infusions (P〈0.05). At the 375 mg/m2 dose, the T1/2 was 122.5±46.7 h vs. 197.0,75.0 11, respectively, and the Cmax was 200.6±20.2 pg/mL vs. 339.1±71.0 ng/mL, respectively. From 250 mg/m2 to 500 mg/m2, the Cmax and AUC increased significantly in a dose-dependent manner (P〈0.05). Patients with a high tumor burden had markedly lower serum SCT400 concenmations compared with those without or with a low tumor burden. Of the 9 assessable patients, 1 achieved complete response and 2 achieved partial responses. Conclusions; SCT400 is well-tolerated and has encouraging preliminary efficacy in Chinese patients with CD20+ B-cell NHL. 展开更多
关键词 Chimeric anti-CD20 monodonal antibody non-Hodgldn's lymphoma phase I study
下载PDF
Clinical study of chemotherapy-related cognitive impairment in patients with non-Hodgkin lymphoma
7
作者 Qiang-Li Wang Hai-Yan Xu +3 位作者 Yi Wang Yin-Ling Wang Pei-Nan Lin Zhong-Lei Chen 《World Journal of Psychiatry》 SCIE 2024年第7期1062-1067,共6页
BACKGROUND Chemotherapy for malignant tumors can cause brain changes and cognitive impairment,leading to chemotherapy-induced cognitive impairment(CICI).Current research on CICI has focused on breast cancer and Hodgki... BACKGROUND Chemotherapy for malignant tumors can cause brain changes and cognitive impairment,leading to chemotherapy-induced cognitive impairment(CICI).Current research on CICI has focused on breast cancer and Hodgkin’s lymphoma.Whether patients with non-Hodgkin’s lymphoma(NHL)undergoing chemo-therapy have cognitive impairment has not been fully investigated.therapy have cognitive impairment has not been fully investigated.AIM To investigate whether NHL patients undergoing chemotherapy had cognitive impairments.METHODS The study included 100 NHL patients who were required to complete a compre-hensive psychological scale including the Brief Psychiatric Examination Scale(MMSE)at two time points:before chemotherapy and within 2 wk of two chemo-therapy courses.A language proficiency test(VFT),Symbol Number Pattern Test(SDMT),Clock Drawing Test(CDT),Abbreviated Daily Cognition Scale(ECog-12),Prospective and Retrospective Memory Questionnaire,and Karnofsky Perfor-mance Status were used to assess cognitive changes before and after chemo-therapy.RESULTS The VFT scores for before treatment(BT)and after treatment(AT)groups were 45.20±15.62,and 42.30±17.53,respectively(t-2.16,P<0.05).The CDT scores were 8(3.5-9.25)for BT and 7(2.5-9)for AT groups(Z-2.1,P<0.05).Retrospective memory scores were 13.5(9-17)for BT and 15(13-18)for AT(Z-3.7,P<0.01).The prospective memory scores were 12.63±3.61 for BT and 14.43±4.32 for AT groups(t-4.97,P<0.01).The ECog-12 scores were 1.71(1.25-2.08)for BT and 1.79(1.42-2.08)for AT groups(Z-2.84,P<0.01).The SDMT and MMSE values did not show a significant difference between BT and AT groups.CONCLUSION Compared to the AT group,the BT group showed impaired language,memory,and subjective cognition,but objec-tive cognition and execution were not significantly affected. 展开更多
关键词 non-hodgkins lymphoma Hodgkin lymphoma lymphoma cognitive impairment Chemotherapy-related cogni-tive impairment Clinical study
下载PDF
SENEX-mediated CDK4/6 inhibition promotes senescence and confers apoptosis resistance in B-cell non-Hodgkin lymphoma
8
作者 JIYU WANG LIUYING YI +3 位作者 KEKE HUANG YANGYANG WANG HUIPING WANG ZHIMIN ZHAI 《BIOCELL》 SCIE 2024年第3期453-462,共10页
Background:The primary cause of treatment failure in patients with refractory or relapsed B-cell non-Hodgkin lymphoma(r/r B-NHL)is resistance to current therapies,and therapy-induced senescence(TIS)stands out as a cru... Background:The primary cause of treatment failure in patients with refractory or relapsed B-cell non-Hodgkin lymphoma(r/r B-NHL)is resistance to current therapies,and therapy-induced senescence(TIS)stands out as a crucial mechanism contributing to tumor drug resistance.Here,we analyzed SENEX/Rho GTPase Activating Protein 18(ARHGAP18)expression and prognostic significance in doxorubicin-induced B-NHL-TIS model and r/r B-NHL patients,investigating its target in B-NHL cell senescence and the effect of combining specific inhibitors on apoptosis resistance in B-NHL-TIS cells.Methods:Raji cells were transfected with the human SENEX shRNA recombinant lentiviral vector(Sh-SENEX)and the empty vector negative(NC)to construct a stable transfection cell line with knockdown of SENEX.Effect of SENEX-silencing on B-NHL-TIS formation,cell function and cell cycle-related pathways was analyzed.Using doxorubicin(DOX)-inducible senescent B-NHL cells combined with the specific cyclin dependent kinase 4/6(CDK4/6)inhibitor Palbociclib to observe that blocking CDK4/6 effects on TIS formation.SENEX expression of 21 B-NHL patients and 8 healthy controls were analyzed by qRT-PCR,and the correlation between its expression and clinical indicators were evaluated.Results:The downregulation of SENEX expression promotes G1-S phase transition and apoptosis while inhibiting cell proliferation,collectively suppressing the formation of TIS in B-NHL.Blockade of CDK4/6 promotes the DOX-induced G1 phase arrest to enhance TIS formation in B-NHL cells which can reverse the regulatory effect of silencing SENEX on B-NHL cell cycle regulation and senescence.The expression levels of SENEX were notably elevated in B-NHL patients compared to healthy controls,and Elevated expression levels of SENEX were associated with poor prognosis of B-NHL patients.Conclusions:SENEX enhances apoptosis resistance in B-NHL by inhibiting CDK4/6,thereby preventing G1-S phase transition and promoting TIS formation. 展开更多
关键词 sENEX B-cell non-hodgkin lymphoma CDK4/6 G1-s phase transition Therapy-induced senescence Apoptosis resistance
下载PDF
Primary Non-Hodgkin’s Malignant Lymphoma of the Uterus at the Reference Hospital of Maradi/Niger: A Case Report
9
作者 Moustapha Elhadji-Chefou Badé Malam-Abdou +5 位作者 Amadou Djibrilla-Almoustapha Maman Brah Moustapha Oumou Kimso Ibrahim Timi Liman Elhadji Ali Issa Abdou Amadou Borges Moreno Yuribet 《Open Journal of Blood Diseases》 2024年第2期43-46,共4页
Malignant non-Hodgkins lymphoma (MHNL) of the uterus is uncommon. We report a case diagnosed on the basis of histologic and immunohistochemical studies of a hysterectomy specimen induced by a very painful pelvic mass ... Malignant non-Hodgkins lymphoma (MHNL) of the uterus is uncommon. We report a case diagnosed on the basis of histologic and immunohistochemical studies of a hysterectomy specimen induced by a very painful pelvic mass in a 50-year-old patient with no previous history of the disease. It was classified as Ann Arbor IV Bb after imaging, given the medullary infiltration and signs of clinical and biological evolutivity: the patient had received two courses of chemotherapy, CHOP protocol. She died 23 days after the second treatment due to a hypertensive crisis. 展开更多
关键词 Malignant non-hodgkins lymphoma UTERUs Referral Hospital Maradi/Niger
下载PDF
Primary early-stage intestinal and colonic non-Hodgkin's lymphoma: Clinical features, management, and outcome of 37 patients 被引量:7
10
作者 Shu-Lian Wang Zhong-Xing Liao +7 位作者 Xin-Fan Liu Zi-Hao Yu Da-Zhong Gu Tu-Nan Qian Yong-Wen Song Jing Jin Wei-Hu Wang Ye-Xiong Li 《World Journal of Gastroenterology》 SCIE CAS CSCD 2005年第37期5905-5909,共5页
AIM: To analyze the clinical features, management, and outcome of treatment of patients with primary intestinal and colonic non-Hodgkin's lymphoma (PICL). METHODS: A retrospective study was performed in 37 patien... AIM: To analyze the clinical features, management, and outcome of treatment of patients with primary intestinal and colonic non-Hodgkin's lymphoma (PICL). METHODS: A retrospective study was performed in 37 patients with early-stage PICL who were treated in our hospital from 1958 to 1998. Their clinical features, management, and outcome were assessed. Prognostic factors for survival were analyzed by univariate analysis using the Kaplan-Meier product-limit method and log-rank test. RESULTS: Twenty-five patients presented with Ann Arbor stage Ⅰ PICL and 12 with Ann Arbor stage Ⅱ PICL. Thirty-five patients underwent surgery (including 31 with complete resection), 22 received postoperative chemotherapy or radiotherapy or both. Two patients with rectal tumors underwent biopsy and chemotherapy with or without radiotherapy. The 5- and 10-year overall survival (OS) rates were 51.9% and 44.5%. The corresponding diseasefree survival (DIS) rates were 42.4% and 37.7%. In univariate analysis, multiple-modality treatment was associated with a better DFS rate compared to single treatment (P= 0.001). While age, tumor size, tumor site, stage, histology, or extent of surgery were not associated with OS and DFS, use of adjuvant chemotherapy significantly improved DFS (P = 0.031) for the 31 patients who underwent complete resection. Additional radiotherapy combined with chemotherapy led to a longer survival than chemotherapy alone in six patients with gross residual disease after surgery or biopsy.CONCLUSION: Combined surgery and chemotherapy is recommended for treatment of patients with PICL, Additional radiotherapy is needed to improve the outcome of patients who have gross residual disease after surgery. 展开更多
关键词 Intestinal neoplasm Colonic neoplasm non-hodgkin's lymphoma surgery Chemotherapy RADIOTHERAPY
下载PDF
A case of primary isolated non-Hodgkin’s lymphoma of the esophagus in an immunocompetent patient 被引量:5
11
作者 Ioannis V Kalogeropoulos Athanasios N Chalazonitis +4 位作者 Sofia Tsolaki Fotios Laspas Nikolaos Ptohis Ioannis Neofytou Dimitra Rontogianni 《World Journal of Gastroenterology》 SCIE CAS CSCD 2009年第15期1901-1903,共3页
Primary non-Hodgkin’s lymphoma of the esophagus is a rare disease.A case of primary isolated nonHodgkin’s lymphoma of the esophagus in a 77-yearold man without acquired immunodeficiency syndrome is presented.We desc... Primary non-Hodgkin’s lymphoma of the esophagus is a rare disease.A case of primary isolated nonHodgkin’s lymphoma of the esophagus in a 77-yearold man without acquired immunodeficiency syndrome is presented.We describe the clinical features and the imaging findings(barium swallow,endoscopic ultrasonography and CT)of a biopsy proven B-cell lymphoma with diffuse transmural involvement of the esophagus wall,which was discovered incidentally.We also briefly review the literature. 展开更多
关键词 Endoscopic ultrasonography EsOPHAGUs lymphoma non-hodgkin's lymphoma
下载PDF
Non-Hodgkin's Lymphoma Primarily Presenting with Fanconi Syndrome and Acute Kidney Injury 被引量:2
12
作者 Wen-ling Ye Bing Han +5 位作者 Bing-yan Liu Chan Meng Wei Ye Yu-bing Wen Hang Li Xue-mei Li 《Chinese Medical Sciences Journal》 CAS CSCD 2010年第3期185-188,共4页
KIDNEY involvement is common in non-Hodgkin's lymphoma (NHL) with incidence up to 30%-40% in autopsy studies. However, it us- ually occurs late in the course of the diseaseand is clinically silent. Clinically overt... KIDNEY involvement is common in non-Hodgkin's lymphoma (NHL) with incidence up to 30%-40% in autopsy studies. However, it us- ually occurs late in the course of the diseaseand is clinically silent. Clinically overt renal disease including acute kidney injury (AKI) as its primary manifestation is rarely reported, moreover, Fanconi syndrome (FS) is extremely rare as the main manifestation in NHL. In this report, we presented a case of NHL primarily presenting with FS and AKI due to diffuse interstitial infiltration of NHL cells and emphasized the important role of renal biopsy, especially renal immunohistochemical analysis in the diagnosis of renal diffuse lymphoma. 展开更多
关键词 non-hodgkin's lymphoma Fanconi syndrome acute kidney injury
下载PDF
Preliminary outcome of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin’s lymphoma: single institution experience 被引量:1
13
作者 Bufei Wang Huiqiang Huang +10 位作者 Qjng Bu Zhongjun Xia Xubin Lin Fenghua Wang Yuhong Li Yulong Peng Zhanhe Pan Shusen Wang Tongyu Lin Wenqi Jiang Zhongzhen Guan 《The Chinese-German Journal of Clinical Oncology》 CAS 2006年第6期402-406,共5页
Objective: The prognosis of relapsed or refractory B-cell lymphoma is poor, with a short-term survival after conventional second-line chemotherapy, Rituximab, a chimeric anti-CD20 antigen, in combination with CHOP or... Objective: The prognosis of relapsed or refractory B-cell lymphoma is poor, with a short-term survival after conventional second-line chemotherapy, Rituximab, a chimeric anti-CD20 antigen, in combination with CHOP or CHOP-like chemotherapy may improve both disease free survival (DFS) and overall survival (OS) of naive patients, but its role in the second-line therapy for relapsed non-Hodgkin's Lymphoma (NHL) remains to be defined, This study aimed to evaluate the efficacy of rituximab-containing salvage regimens for relapsed or refractory NHL, and observe the toxicities. Methods: The clinical data of 54 patients, who were with relapsed or refractory NHL and treated in the Cancer Center of Sun Yat-sen University, were analyzed retrospectively, Of the 54 patients, 29 were man, 25 were women, with a median age of 52.5 years old (range 18 to 75); 50 patients (92.6%) scored 0-1 for the ECOG performance status; for second-line international prognostic index (slPI), 21 (38.9%) scored 0-1,30 (55.6%) scored 2 to 3, and 3 (5.6%) scored 4-5; 40 cases were diffuse large B-cell lymphoma (DLBCL), accounting for 74.1% of all subtypes, Rituximab was administered intravenously at a dose of 375 mg/m^2 at the day before each chemotherapy cycle, The second or third-line salvage regimens included EPOCH, CHOP, DHAP, DICE, IVAC, IMVP-16 and FND, Results: Of the 54 patients, 49 received retuximab-containing salvage regimens, The objective response rate of the 45 evaluable cases was 68,8%, with a complete remission (CR) rate of 37.7%; 3 patients achieved CR after radiotherapy following rituximab-based regimens and 3 achieved CR after autologous hematopoietic stem cell transplantation, The most frequent adverse events were leucopenia, nausea and alopecia. The addition of rituximab to chemotherapy only elevated the occurrence of mild infusion-related reactions, such as chills, fever and pruritus. The median follow-up time was 18 months (range 2-86 months); 5 patients were lost, 24 were dead (23 died of lymphoma, and 1 died of severe hepatitis), the other patients remained alive. The median survival time was 32 months (range 2-86 months, 95% confidential interval 16-48 months). The 1-, 2- and 3-year OS rates were 70.6%, 53,6% and 41,5%, respectively, The median TTP was 6 months (range 0-52 months), The median PFS was 10 months (range 0-47 months, 95% CI 0-26 months), The 1- and 2-year PFS were 49,3% and 41,3%. Conclusion: Rituximab-containing salvage regimens are effective and well tolerated therapy for patients with relapsed or refractory B-cell NHL, even those were extensively treated. 展开更多
关键词 non-hodgkin's lymphoma chemotherapy RITUXIMAB salvage treatment
下载PDF
Analysis of Efficacy of DICE(Dexamethasone,Ifosfamide,Cisplatin and Etoposide)Regimen on Recurrent and Refractory Intermediate and High Grade Non-Hodgkin's Lymphoma 被引量:1
14
作者 Lei Yang Zhucheng Song Xiaohong Xu Jinzhi Wei Qinghe Tan Zhirong Cong Chunlei Peng 《Chinese Journal of Clinical Oncology》 CSCD 2009年第1期59-63,共5页
OBJECTIVE Thus far there is no standard salvage regimenfor patients with recurrent and refractory intermediate and highgrade non-Hodgkin's lymphoma (NHL). This study intends toinvestigate the therapeutic efficacy ... OBJECTIVE Thus far there is no standard salvage regimenfor patients with recurrent and refractory intermediate and highgrade non-Hodgkin's lymphoma (NHL). This study intends toinvestigate the therapeutic efficacy of the DICE (dexamethasone,isofosfamide, cisplatin and etoposide) regimen on the recurrentand refractory NHL, and to observe the related adverse effects.METHODS Clinical records of 22 patients with recurrent andrefractory NHL, who failed to achieve a remission from theCHOP [cyclophosphamide, hydroxydaunomycin/doxorubicin(adriamycin), oncovin, prednisone] regimen within 2 to 6 cyclesof treatment, were reviewed. DICE, as a salvage regimen with amedian course of treatment of 4 cycles (ranging from 2 to 7 cycles),was now used, and evaluation of the therapeutic efficacy andadverse effect of DICE was conducted in all the patients. Of the 22NHL cases, 8 were of T-cell origin and the other 14 B-cell origin.Salvage treatment was performed in the patients, with appraisal,prevention and treatment of the toxic reactions.RESULTS Following DICE treatment in the 22 patients, thetotal effective rate of the regimen was 63.6%, and the completeremission (CR) rate was 40.9%. The effective rates of DICE onthe T and B-cell sourced NHL were 75.0% and 57.1%, and the CRrate were 37.5%, 42.9%, respectively (P >0.05). An increase of thelactate dehydrogenase (LDH) level accompanied by a giant lumpwas the short-term effect on patients with recurrence (mean P <0.05) who were drug resistant. Myelosuppression, digestive systemreaction and alopecia were the commonly-seen complications inthe patients who received DICE regimen. All patients recoveredafter treatment, and no chemotherapy-related death occurred.CONCLUSION DICE regimen is effective in treating refractoryand recurrent NHL. 展开更多
关键词 non-hodgkin's lymphoma chemotherapy DICE regimen therapeutic effect adverse effect.
下载PDF
Expression of P120 Catenin mRNA in Non-Hodgkin's Lymphoma Cell Lines
15
作者 吴颖 刘文励 +2 位作者 孙汉英 周洪升 徐慧珍 《Journal of Huazhong University of Science and Technology(Medical Sciences)》 SCIE CAS 2006年第2期185-187,共3页
To investigate p120 catenin mRNA expression in Non-Hodgkin's lymphoma (NHL) cell lines (U937, Raji, Jurkat and Molt4) and normal lymphocytes and explore the relationship between p120 catenin and Non-Hodgkin's ly... To investigate p120 catenin mRNA expression in Non-Hodgkin's lymphoma (NHL) cell lines (U937, Raji, Jurkat and Molt4) and normal lymphocytes and explore the relationship between p120 catenin and Non-Hodgkin's lymphoma, total RNA sample was extracted by using TRIzol and reversely transcripted into cDNA. Polymerase chain reaction was performed to detect mRNA expression of p120 catenin in NHL cell lines U937, Raji, Jurkat and Molt4. Normal lymphocytes were used as control. It was found expressions of p120 catenin 1A and 3A mRNA were high in above-mentioned NHL cell lines, but neither p120 catenin 1A nor 3A was found in normal lymphocytes as shown by RT-PCR. It is concluded that both P120ctnlA and P120ctn3A mRNA transcripts were found in all NHL cell lines U937, Raji, Jurkat and Molt4 but they don't exist in normal lymphocytes, suggesting pl20cm possibly is of importance in diagnosis and therapy of lymphoma. 展开更多
关键词 non-hodgkin's lymphoma P120CTN RT-PCR
下载PDF
Prognostic values of serum LDH and β2-MG in patients with non-Hodgkin’s lymphoma
16
作者 Lei Yang Xiaohong Xu Chunlei Peng Jinzhi Wei Zhuchen Song Zhirong Cong 《The Chinese-German Journal of Clinical Oncology》 CAS 2009年第6期353-355,共3页
Objective: To evaluate the clinical significance of quantitative determination of serum lactic dehydrogenase (LDH) and beta 2-microgtobulin (β2-MG) in patients with non-Hodgkin's lymphoma (NHL). Methods: Dat... Objective: To evaluate the clinical significance of quantitative determination of serum lactic dehydrogenase (LDH) and beta 2-microgtobulin (β2-MG) in patients with non-Hodgkin's lymphoma (NHL). Methods: Date of the 65 patients from 2003 to 2004 were retrospectively analyzed, relationship between LDH and β2-MG activities and tumor phase, effect of treat- ment as well as prognosis were studied. Results: The levels of LDH and β2-MG in the advanced stage, B group and bone marrow involvement were obviously higher than their comparison counterpart and the difference was significant (P 〈 0.05). There was no significant difference between the high LDH group and normal LDH group in the two-year survival rate. But the difference in the four-year survival rate was significance. Conclusion: The level of LDH and β2-MG are valuable for clinical stage, prognosis and evaluation of therapeutic response in patients with NHL. 展开更多
关键词 lactic dehydrogenase beta 2-microglobulin non-hodgkin's lymphoma PROGNOsIs
下载PDF
Clinical randomized comparative trial of DICE regimen and CHOP regimen in treating intermediate and high grade non-Hodgkin’s lymphoma
17
作者 Wenwu Wang Xuenong OuYang Zhangshu Cheng Yonghai Peng Fangwei Xie Zongyang Yu 《The Chinese-German Journal of Clinical Oncology》 CAS 2008年第2期107-110,共4页
Objective: To compare efficacies and safeties of DICE and CHOP regimens in treating intermediate and high grade non-Hodgkin's lymphoma (NHL), and indicate the standard treatment for it. Methods: A total of 74 pati... Objective: To compare efficacies and safeties of DICE and CHOP regimens in treating intermediate and high grade non-Hodgkin's lymphoma (NHL), and indicate the standard treatment for it. Methods: A total of 74 patients with moder- ately or highly malignant NHL, verified by pathology or histology, were randomized into the trial group (37 patients treated with DICE regimen) and the control group (37 patients treated with CHOP regimen). Survival rate was analyzed by Kaplan-Meier method. Chi-square test was performed between groups. Results: The complete response rate, partial response rate, and response rate were significantly higher in DICE group than in CHOP group (40.5% vs. 29.7%, 37.8% vs. 27.0%, and 78.3% vs. 56.7%, respectively, P < 0.05). The 1-, 3-, and 5-year survival rates were significantly higher in DICE group than in CHOP group (89.2% vs. 81.2%, 76.0% vs. 52.6%%, and 46.7% vs. 36.4%, respectively, P < 0.05). The major side effects, appeared with no differences (P > 0.05) in incidences between the two groups, were leukopenia, thrombocytopenia, and nausea. There were only three episodes of clinical cystitis or gross haematuria in DICE regimen. Conclusion: The results showed higher efficacy of DICE regimen over CHOP regimen. DICE regimen may prolong the survival time of patients with moderately and highly malignant NHL. 展开更多
关键词 non-hodgkin's lymphoma combined chemotherapy comparative trial
下载PDF
Clinical characteristics for 112 cases with non-Hodgkin’s lymphoma
18
作者 Qin Zhang Zhongping Jiang Xingquan Jin 《The Chinese-German Journal of Clinical Oncology》 CAS 2008年第9期546-548,共3页
Objective: To study clinical characteristics of non-Hodgkin's lymphoma (NHL) in order to diagnose and treat early and improve prognosis. Methods: 112 cases with NHL were pathologically diagnosed and treated in 19... Objective: To study clinical characteristics of non-Hodgkin's lymphoma (NHL) in order to diagnose and treat early and improve prognosis. Methods: 112 cases with NHL were pathologically diagnosed and treated in 1992-2005. Results: Among all cases, 30 were not treated previously, 79 were involved in peripheral lymph nodes, 55 deep lymph nodes, 18 Waldeyer's ring, 25 respiratory system, 26 digestive system, 26 spleen, 13 bone, 13 skin and subcutaneous, 4 urinogenital system, 13 other sites. Among 30 previously untreated patients, there were 4 staged 1, 3 IE1 5 Ⅱ, 1 ⅡE, 9 Ⅲ, 1 Ⅲs and 7 IV. Among 82 patients with prior treatment, 29 were involved in lymph nodes only, 53 involved in different organs and tissues. In our series, there were 38 cases and 74 cases belonged to subtype A and subtype B respectively. Conclusion: The enlargement of peripheral lymph nodes is main clinical characteristic in NHL, but lesions also involve different organs and tissues. The diagnosis of NHL depends upon pathological examination. 展开更多
关键词 non-hodgkin's lymphoma (NHL) clinical characteristic DIAGNOsIs
下载PDF
The expressions of CD147 and MMP-9 in non-Hodgkin's lymphoma cells and the relation to prognosis
19
作者 Aiguo Liu Qun Hu Shuangyou Liu Ying Hu 《The Chinese-German Journal of Clinical Oncology》 CAS 2009年第12期705-708,共4页
Objective: The aim of this study was to investigate the expression of CD147 and matrix metalioprpteinsae 9 (MMP-9) in children with non-Hodgkin's lymphoma (NHL) and the relations between expressions of CD147 & ... Objective: The aim of this study was to investigate the expression of CD147 and matrix metalioprpteinsae 9 (MMP-9) in children with non-Hodgkin's lymphoma (NHL) and the relations between expressions of CD147 & MMP-9 and the clinical indexes. Methods: Specimens excised from NHL patients were prepared. Expression of CD147 and MMP-9 were tested by SABC immunohistochemistry and its correlation to clinical results were analyzed in this report. Results: The positive rate of CD147 expression was 73% (45/62), and that of MMP-9 expression was 81% (50/62). There was a positive correlation between CD147 and MMP-9 expressions. CD147 expression intensity was linked to clinical myelo-infiltration, tumor size, LDH value, and clinical staging (P 〈 0.05), rather than children age, gender, or immune typing (P 〉 0.05); MMP-9 expression intensity was linked to myelo-infiltration, and clinical staging (P 〈 0.05), rather than age, gender, immune typing, tumor size, or LDH value (P 〉 0.05). Five-year survival rates were 78% (22/28) and 45% (15/34) in CD147 (-)-(+) and (++)-(+++) cases respectively, and those were 84% (21/25) and 43% (16/37) in MMP-9 (-)-(+) and (++)-(+++) cases respectively, the difference was significant. Conclusion: The elevated expression of CD147 and/or MMP-9 correlates with a poor clinical outcome in patients with NHL. 展开更多
关键词 CD147 matrix metalloproteinase 9 (MMP-9) non-hodgkin's lymphoma (NHL)
下载PDF
Analysis of Clinical Manifestations and Prognosis of 92 Cases with Non-Hodgkin's Lymphoma
20
作者 Xianlin Duan Ming Jiang 《Chinese Journal of Clinical Oncology》 CSCD 2008年第3期195-199,共5页
OBJECTIVE To analyze the risk factors and influence of various treatments on the prognosis of non-Hodgkin's lymphoma (NHL). METHODS Clinical data of 92 patients with NHL from our hospital were retrospectively revi... OBJECTIVE To analyze the risk factors and influence of various treatments on the prognosis of non-Hodgkin's lymphoma (NHL). METHODS Clinical data of 92 patients with NHL from our hospital were retrospectively reviewed.Kaplan-Meier statistics were used to analyze the differences in survival times of the patients receiving various treatments.Cox regression model was employed for analyzing the prognostic factors. RESULTS Among our patients,the 2 and 5-year disease-free survivals (DFS) were respectively 68%and 51%.The 5-year cancer-specific survival (CSS) was 55%.Mono-factorial analysis showed that the main independent prognostic factors included Ann Arbor Staging,B symptoms,lactate dehydrogenase (LDH),the international prognostic index (IPI) and age.Concerning the IPI,the 5-year CSS for the low-risk factors(0~1),lower-moderate risk (2),higher-moderate(3) and high-risk (4~5) were respectively 60%,62%,42% and 33%.Analysis of the prognoses,based on treatment of the patients with different stages,was as follows:the 5-year survival rates of the Stage-Ⅰ and Ⅱ patients,receiving surgery or chemotherapy alone,or a combined therapy,were respectively 19%,72% and 68%,showing that the survival rates of the group with a combined therapy and the chemotherapy alone were superior to the group with surgery alone;the 5-year survival rates of the Stage-Ⅲ and Ⅳ patients,receiving surgery or chemotherapy alone or a combined therapy,were respectively 50%,35% and 60%,indicating that the survival rate of the group with a combined therapy was superior compared to the group with chemotherapy alone. CONCLUSION Long-term survival of non-Hodgkin's lymphoma patients is closely related with multiple factors. Rational detection and assessment of the risk factors may prolong the living time of the patients.Different methods of treatment can influence the patient's prognosis.Correct evaluation of the prognostic factors,and rational and effective therapy can prolong the patient's survival. 展开更多
关键词 non-hodgkin's lymphoma PROGNOsIs survival rate
下载PDF
上一页 1 2 32 下一页 到第
使用帮助 返回顶部